Serena Oliveri1,2, Giulia Ongaro3,4, Ilaria Durosini4, Giuseppe Curigliano3,5, Gabriella Pravettoni3,4. 1. Department of Oncology and Hematoncology (DIPO), University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy. serena.oliveri@unimi.it. 2. Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology (IEO), IRCCS, Milan, Italy. serena.oliveri@unimi.it. 3. Department of Oncology and Hematoncology (DIPO), University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy. 4. Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology (IEO), IRCCS, Milan, Italy. 5. Division of Early Drug Development for Innovative Therapy, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Abstract
PURPOSE: During the last two decades, the number of breast implants used in aesthetic, oncologic, and risk-reducing surgery has increased substantially mainly due to the improvement and confirmed safety of these devices. Since the identification of the first case of anaplastic large cell lymphoma associated with a breast implant (BIA-ALCL) 20 years ago, there has been an increase in the number of reports of this very rare disease, demonstrating a clear association with breast implants. While the majority of cases are localized and cured by implant removal and full capsulectomy, a small percentage require chemotherapy and the mortality rate is very low. Nevertheless, the evidence linking BIA-ALCL to implant surface texturing has raised concerns about the long-term safety of these devices resulting in patient and regulatory authority concerns globally. METHODS AND RESULTS: In this commentary, we report the current debate on BIA-ALCL and the main European government's actions, with a special focus on the emotional impact that media coverage has on cancer patients. We comment the emotional impact of such risk for patients with breast implant, the hard process of patient's acceptance for mastectomy and reconstructive surgery, and how this is an essential part of recovery and return to the normal living for many women. CONCLUSION: We conclude by providing guidelines for patient-physician communication and patients' psychological support on this topic of delicate actuality. Our contribution aims at guiding the medical community in managing risk communication about BIA-ALCL with a multidisciplinary approach, according to the most recently available published evidence.
PURPOSE: During the last two decades, the number of breast implants used in aesthetic, oncologic, and risk-reducing surgery has increased substantially mainly due to the improvement and confirmed safety of these devices. Since the identification of the first case of anaplastic large cell lymphoma associated with a breast implant (BIA-ALCL) 20 years ago, there has been an increase in the number of reports of this very rare disease, demonstrating a clear association with breast implants. While the majority of cases are localized and cured by implant removal and full capsulectomy, a small percentage require chemotherapy and the mortality rate is very low. Nevertheless, the evidence linking BIA-ALCL to implant surface texturing has raised concerns about the long-term safety of these devices resulting in patient and regulatory authority concerns globally. METHODS AND RESULTS: In this commentary, we report the current debate on BIA-ALCL and the main European government's actions, with a special focus on the emotional impact that media coverage has on cancerpatients. We comment the emotional impact of such risk for patients with breast implant, the hard process of patient's acceptance for mastectomy and reconstructive surgery, and how this is an essential part of recovery and return to the normal living for many women. CONCLUSION: We conclude by providing guidelines for patient-physician communication and patients' psychological support on this topic of delicate actuality. Our contribution aims at guiding the medical community in managing risk communication about BIA-ALCL with a multidisciplinary approach, according to the most recently available published evidence.
Entities:
Keywords:
BIA-ALCL; Breast prostheses; Decision-making; Personalized medicine; Psychological support; Quality of life
Authors: Courtney A Gidengil; Zachary Predmore; Soeren Mattke; Kristin van Busum; Benjamin Kim Journal: Plast Reconstr Surg Date: 2015-03 Impact factor: 4.730
Authors: David J Collett; Hinne Rakhorst; Peter Lennox; Mark Magnusson; Rodney Cooter; Anand K Deva Journal: Plast Reconstr Surg Date: 2019-03 Impact factor: 4.730
Authors: Maurizio Bruno Nava; William P Adams; Giovanni Botti; Antonella Campanale; Giuseppe Catanuto; Mark W Clemens; Daniel A Del Vecchio; Roy De Vita; Arianna Di Napoli; Elisabeth Hall-Findlay; Dennis Hammond; Per Heden; Patrick Mallucci; Josè Luis Martin Del Yerro; Egle Muti; Alberto Rancati; Charles Randquist; Marzia Salgarello; Constantin Stan; Nicola Rocco Journal: Plast Reconstr Surg Date: 2018-01 Impact factor: 4.730
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: Mintsje de Boer; Flora E van Leeuwen; Michael Hauptmann; Lucy I H Overbeek; Jan Paul de Boer; Nathalie J Hijmering; Arthur Sernee; Caroline A H Klazen; Marc B I Lobbes; René R W J van der Hulst; Hinne A Rakhorst; Daphne de Jong Journal: JAMA Oncol Date: 2018-03-01 Impact factor: 31.777
Authors: Stephen L Brown; Demian Whiting; Hannah G Fielden; Pooja Saini; Helen Beesley; Christopher Holcombe; Susan Holcombe; Lyn Greenhalgh; Louise Fairburn; Peter Salmon Journal: PLoS One Date: 2017-05-26 Impact factor: 3.240
Authors: Evan B Lynch; Ryan C DeCoster; Krishna S Vyas; Brian D Rinker; Mei Yang; Henry C Vasconez; Mark W Clemens Journal: Ann Breast Surg Date: 2021-09-30
Authors: Ilaria Durosini; Lucrezia Savioni; Stefano Triberti; Paolo Guiddi; Gabriella Pravettoni Journal: Int J Environ Res Public Health Date: 2021-01-22 Impact factor: 3.390